Clinical trials: Buprenorphine
Tobacco Dependence
Tobacco Intervention in Buprenorphine Treatment
Drug addiction treatment patients, including those in treatment for opioid dependence, have a high rate of tobacco dependence, especially cigarette smoking.
- Trial name
- IBIS (NCT01350011)
- Testing
- Innovative System, Standard Treatment Control (STC)
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pain, Pharmacokinetics
Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours
The purpose of the study was to investigate the pharmacokinetics (i.e. the uptake, distribution and elimination from the body) of dermally applied buprenorphine during and after different application periods, i.e., a 96-hour and…
- Trial name
- NCT03770234
- Testing
- Transtec 35 µg/hour transdermal patch
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Opioid-use Disorder
Project STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention Through NAvigation)
Project STAMINA is a clinical trial that seeks to establish effectiveness of a telemedicine approach for linking syringe exchange clients to medications for opioid use disorder.
- Trial name
- STAMINA (NCT04575324)
- Testing
- Telemedicine Linkage Intervention
- Where
- United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Chestnut Health Systems
Cocaine-related Disorders
Buprenorphine Naltrexone-P1 A-Cocaine
The purpose of this study is to determine if the opioid agonist effects of doses of 4/1 mg, 8/2 mg, and 16/4 mg of buprenorphine/naloxone can be completely blocked by 50 mg of oral naltrexone.
- Trial name
- NCT00733720
- Testing
- Suboxone
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-use Disorder, Opioid Dependence
Comparing Home, Office, and Telehealth Induction for Medication Assisted Treatment for Opioid Use Disorder
HOMER is a national study comparing three methods of induction for Medication Assisted Treatment (MAT) for Opioid Use Disorder (OUD); home versus office versus telehealth-based inductions.
- Trial name
- HOMER (NCT04664062)
- Testing
- Medication Assisted Treatment
- Where
- 2 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hepatitis C
Drug Interaction & Methadone & Buprenorphine
The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in subjects with the stable dose of Methadone and on…
- Trial name
- NCT02045693
- Testing
- Methadone, DCV 3DAA FDC, BMS-791325
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir
The main purpose of this study is to examine the effect of tipranavir combined with ritonavir, medications for the treatment of HIV-infection, on buprenorphine/naloxone (BUP) in people who have been receiving the same dose of…
- Trial name
- BUTI (NCT00486330)
- Testing
- Buprenorphine, Tipranavir and ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
Opioid-Related Disorders, Opioid Withdrawal
Comparison of Three Opioid Detoxification Treatment Regimens
Despite an increased focus on treating opioid use disorder there are relatively few studies that compare the length of time required for detoxification with medications other than buprenorphine.
- Trial name
- NCT03678792
- Testing
- Buprenorphine/naloxone, Morphine, Tramadol
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
HIV Infections, Opioid-Related Disorders
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
Drug abuse and HIV/AIDS are serious global health problems. Injection drug use is currently the major mode of transmission of HIV in many countries.
- Trial name
- NCT00270257
- Testing
- Buprenorphine/Naloxone
- Where
- 4 sites in China, Thailand
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Pain
Dronabinol Opioid Sparing Evaluation (DOSE) Trial
This study will be a 12-week, open-label trial that is designed to evaluate the Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid analgesics that are currently being prescribed to patients…
- Trial name
- NCT03766269
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Daisy Pharma Opioid Venture, LLC
Opioid-related Disorders, Buprenorphine
Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users
The purpose of this study is to examine how Buprenorphine, a form of opioid addiction treatment, changes the ability to think and reason among people addicted to opiates, who are either HIV negative or HIV positive.
- Conditions
- Opioid-related Disorders, Buprenorphine, HIV, Cognition
- Trial name
- NCT01108679
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Addiction
To Test a Payer/Treatment Agency Intervention to Increase Use of Buprenorphine
A team of researchers from the University of Wisconsin-Madison College of Engineering and Oregon Health \& Science University will test whether clinician training and the use of organizational change strategies are sufficient for…
- Trial name
- NCT01702142
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthy
A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone
A single-dose pilot study of an investigational capsule formulation of 2 mg/.05 mg Buprenorphine/Naloxone. NIDA Contract No. HHSN271200577414C
- Trial name
- NCT00880841
- Testing
- Buprenorphine / Naloxone
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- NanoSHIFT LLC
Opioid Use Disorder, Opioid Use Disorder, Severe
Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses
This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine…
- Conditions
- Opioid Use Disorder, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
- Trial name
- BISTRO (NCT07631598)
- Testing
- Standard of Care Referral, Low Threshold Buprenorphine
- Where
- 8 sites in United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Substance Use Disorders, Overdose
Emergency Medicine Peer Outreach Worker Engagement for Recovery
This is an observational, prospective case-control study evaluating the effects of an emergency department community health worker-peer recovery specialist program (PCHW), the Substance Misuse Assistance Response Team (SMART).
- Conditions
- Substance Use Disorders, Overdose, Opioid Use Disorder, Alcohol Use Disorder
- Trial name
- EMPOWER (NCT06320015)
- Testing
- Substance Misuse Assistance Response Team (SMART), Usual Care Group
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Renal Impairment
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.
- Trial name
- NCT02508506
- Testing
- ALKS 5461
- Where
- 3 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Opioid-use Disorder, Opioid Use, Unspecified
Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution…
- Conditions
- Opioid-use Disorder, Opioid Use, Unspecified, Buprenorphine Dependence
- Trial name
- Mother/BabyOUD (NCT03923374)
- Testing
- Subutex / Buprenorphine, Fetal & Neonatal MRI, DNA/Genetic/Pharmacokenetic Blood Draws
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Senthil Sadhasivam
Opioid-use Disorder
Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology
This study will assesses the efficacy of buprenorphine/naloxone vs buprenorphine on maternal withdrawal symptoms and drug cravings.
- Trial name
- NCT03740243
- Testing
- Buprenorphine/naloxone, Buprenorphine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Stony Brook University
Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine
Effects of Posaconazole and Voriconazole on the Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine
Variability in drug response can be due to either pharmacokinetic or pharmacodynamic factors. The reasons why people differ in pharmacokinetics or pharmacodynamics are manifold and include, e.g., genetic factors, diseases, age…
- Trial name
- PosaBupre (NCT01367808)
- Testing
- vorikonazole, posakonazole
- Where
- Finland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Opioid-use Disorder
Study of a Novel Subcutaneous Depot Formulation of Buprenorphine
INDV-6200 is being developed for the treatment of opioid dependency and is expected to provide sustained buprenorphine plasma concentrations.
- Trial name
- NCT03715634
- Testing
- INDV-6200, SL Buprenorphine, Nalorex
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.